Kornimate/medical-research-clean huggingface dataset:
validation of low anterior resection syndrome score in korean version

Conditions: Neoplasm of Rectum; Surgery--Complications; Surgery

Summary: in contemporary era of rectal cancer treatment, development of surgical technique and tool, adaptation of chemoradiation therapy, as well as multidisciplinary approach have led increased survival as well as rate of sphincter preservation. however, poor anorectal function, such as fecal incontinence and/or urgency, has also been increased. such anorectal dysfunction is named as low anterior resection syndrome, and its rate has been reported in 40 to 90% in rectal cancer patients who received sphincter preserving surgery. low anterior resection syndrome is known to debilitate quality of life in survivors of rectal cancer. previously, several studies attempted to evaluate the low anterior resection syndrome via questionnaires and scoring system. adapting the low anterior resection syndrome score system created in denmark, this study investigates the validity of the scoring system in korean language.

in this study, the low anterior resection syndrome score questionnaire proposed by therese juul is translated to korean language by 3 different professional translators. patients who received sphincter saving surgery to treat rectal cancer will be asked to fill up the questionnaire. compiling the results, the quality of life after sphincter preserving surgery will be investigated in the association with the low anterior resection syndrome.

Eligibility criteria:
inclusion criteria: * age 20-80 * surgery undertook from jan. 2009 to dec. 2016 * diagnosed with adenocarcinoma * curative intent of surgery * planned surgery * sphincter saving surgery exclusion criteria: * patients with stage iv * emergency surgery * patients with recurrent disease
a study of leuprolide acetate depot in children with central precocious puberty

Conditions: Central Precocious Puberty

Summary: the main aim is to see how leuprolide works to treat central precocious puberty in children. participants will receive an injection of leuprorelin acetate depot 11.25 mg every 12 weeks during 6 months and will visit their study clinic 6 times to complete some assessments.

the drug being tested in this study is called leuprorelin acetate depot 3m. leuprorelin acetate depot 3m will be tested to treat children who have central precocious puberty. this study will look at the efficacy and safety of leuprorelin acetate depot 3m in the treatment of cpp. the study will enroll approximately 80 participants with cpp. participants with a bodyweight of ≥ 20 kg will receive the recommended dose of leuprorelin acetate depot 3m in a 24 weeks treatment period followed by a 12 weeks post-treatment follow-up period. participants will be assigned to the following drug administration: • leuprorelin acetate depot 3m 11.25 mg participants will receive leuprorelin acetate depot 3m 11.25 mg as subcutaneous (sc) injection on weeks 0, 12, and 24. the gonadotropin-releasing hormone agonist (gnrha) stimulation, basal luteinizing hormone (lh), and follicle-stimulating hormone (fsh) levels will be tested pre-dose of every sc injection of the study drug or at premature termination. this multi-center trial will be conducted in china. the overall time to participate in this study is 38 weeks. participants will make a follow-up visit to the site at approximately 12 weeks after the last dose of study treatment.

Eligibility criteria:
inclusion criteria: 1. maximum age to participate is this study is up to 10 years (child). early appearance of secondary sexual characteristics: girls ≤8 years, boys ≤9years 2. body weight ≥20 kg 3. according to the national consensus statement in china (2015), cpp is diagnosed when secondary sexual characteristics appeared before the age of 8 years in girls and 9 years in boys, a peak lh level \>5.0 iu/l with lh/fsh \>0.6 in stimulating test; evidence of gonadal development by ultrasonography (multiple ovarian follicles ≥4 mm in any ovary or uterine enlargement in females or testicular volume ≥4 ml in males); advanced bone age (ba) ≥1 year; linear growth acceleration with higher growth velocity (gv) than normal children. ba is determined by greulich and pyle standards or tw3 standards at screening. exclusion criteria: 1. the participant has received gnrha treatment in a previous clinical study or as a therapeutic agent. 2. the participant has a history or clinical manifestations of significant adrenal or thyroid diseases or intracranial tumor or has a history of malignant disease. 3. the participant has a history of hypersensitivity or allergies to leuprorelin, or related compounds including any excipients of the compound. 4. the participant has a diagnosis of peripheral precocious puberty.

Keywords: drug therapy
prospective evaluation of topical almond oil vs hydroquinone

Conditions: Skin Pigmentation

Summary: the purpose of this study is to analyze facial pigmentation and skin microbiome changes after topical almond oil application, compared to the use of topical hydroquinone.

the purpose of this experiment is to analyze facial pigmentation and skin microbiome changes after topical almond oil application, compared to the use of topical hydroquinone. there will be a total of 50 subjects: * 25 randomized to receive almond oil nightly * 25 randomized to receive 2% hydroquinone nightly study timelines: * the duration of an individual subject's participation will last from the day of the consent/screening (visit 1) until visit 5 where they will have images taken and measurements collected to assess skin pigment, skin hydration, sebum excretion rate. * the duration of participation is 4 months. * the estimated time for the investigators to complete primary analysis is 2 years.

Eligibility criteria:
inclusion criteria: * premenopausal women of fitzpatrick skin types 3 to 6 exclusion criteria: * those with a nut allergy * smoking is an independent risk factor and serves as a confounder for the development of facial aging \[18\]. therefore current smokers, those that have smoked within the past year, and former smokers with greater than a 20 pack year history of smoking will be excluded. * those with an autoimmune photosensitive condition or a known genetic condition with a deficiency in collagen production (such as ehlers-danlos syndrome) will be excluded as this can be a confounder for facial photoaging. * hormonal medications or therapies will not be allowed unless they have been stable on their medications for at least 2 months. examples include oral contraceptives, progesterone-based injections, and estrogen based hormonal replacement therapy. * those who have undergone any cosmetic procedures to the face in the 4 months prior to enrollment in the opinion of the investigator. people that have undergone deeper chemical peels (tca based peels) within 1 year prior to enrollment will also not be eligible. * individuals who are unwilling to discontinue vitamin e containing supplements and food sources during the washout and intervention. * individual who are unwilling to discontinue topical cosmetic products during the duration of the study. * individuals who are not willing to engage in a two-week washout on topical treatments known to affect facial pigmentation and these agents will be restricted during the study period as well. these include topicals that contain: * retinoids such as tretinoin, adapalene, retinol. * antioxidant ingredients such as vitamin c or vitamin e. * pigment-reducing agents such as hydroquinone, azelaic acid, kojic acid per the discretion of the investigator except for the hydroquinone that is provided in this study. * topicals that contain a nut oil or nut extract as part of their ingredient list. * furthermore, subjects will be asked to refrain from use of any other topical products for one week prior to each visit apart from the study agents supplied from this study.
visual dependence and multisensory balance rehabilitation after stroke

Conditions: Stroke; Balance; Distorted; Gait, Unsteady

Summary: this cross-sectional study aims to investigate the prevalence of post-stroke visual dependence, and the effects of visual dependence on balance and gait. it also determines whether visual dependence could differentiate stroke patients with a history of falls from without.

stroke participants will be recruited to measure the level of visual dependence, muscle strength, neurological recovery, balance ability, vertigo symptom, gait pattern and activities of daily living. this will calculate the prevalence of post-stroke visual dependence, and investigate the negative impact of visual dependence on balance and walking functions. this also determines whether the value of visual dependence could differentiate stroke patients with a history of falls from without a history of falls.

Eligibility criteria:
inclusion criteria: * 1) first stroke with 20-80 years of age * 2) the time since onset is more than 6 months * 3) can walk independently at least 10 meters without any walking devices and orthosis * 4) normal cognitive function with scoring more than 24 on the mini mental state examination scale * 5) can understand and follow commands * 6) can give informed consent exclusion criteria: * 1) other neurological disorders which could affect balance assessment * 2) cerebellar stroke * 3) diagnosis with central or peripheral vestibular diseases.
test of discomfort and malaise of two different urine catheters in healthy volunteers

Conditions: Spinal Cord Injury

Summary: the purpose of this study is to evaluate the safety of a new developed catheter in comparison with an catheter on the market. the study is randomised.

intermittent catheterization is the preferred method for emptying the bladder in patients with spinal cord injury and neurogenic bladder dysfunction. coloplast has developed a new intermittent catheter. in this investigation this new test catheter will be compared with speedicath by assessing discomfort and pain associated with catheterization of healthy men. the reason for choosing healthy men is that many catheter users do not have full feeling in their urethra and therefore can not assess the discomfort. healthy men who are ≥ 18 years and have no signs of urinary tract infection and do not have abnormalities, disease or have had operational interventions in the urinary tract will be included. they are recruited through advertisements on the website www.forsoegsperson.dk.

Eligibility criteria:
inclusion criteria: * 18 years or older * male * signed informed consent, * neg. urine multistix exclusion criteria: * abnormalities, * diseases or surgical procedures performed in the lower urinary-tract
the effect of different modialites of varicocelectomy on semen parameters in patient with normal semen analysis

Conditions: Varicocele

Summary: to evalute the effect inguinal and subinguinal approach of varicoceclectomy on semen parameter for patients complaining of varicocele with normal semen parameter (pain is the main complaint)

the varicocele is defined as dilated and incompetent veins within the pampiniform plexus of spermatic cord. varicocele has been described as the most common surgically correctable cause of male subinfertility.this is a disease that devolops during puberty when both endocrine and exocrine function of the testicle dramatically increases, along with testicular blood flow. varicocele only rarely detected in boys less than 10 years. left sided varicocle found in 15% of healthy young men.incontrast, the incidence in sub fertile men approaches 40% bilateral varicocele is uncommon in healthy men (less than 10%) but palpated in 20% in sub fertile men. in-general varicocele don't spontaneously regress. an accurate physical examination remain the corner stone of varicocele diagnosis. several anatomic features contribute to the predominance of left sided varicocele is the left intrnal spermatic vein longer than the right and it typically joins the left renal vein at a right angle.as result of this character higher venous pressures fair transmited to the left spermatic vein and result in reterograde reflux of blood. varicocle are associated with testicular atrophhy and varicocle correction can reverse atrophy in adolececnt. there is strong evidence affect semen quality it can cause abnormalties in concentration, motility and morphology.main defect is the motility. indication of varicocelectomy: 1. large varicoceles in adolescents 2. childhood varicocele with testicular atrophy 3. varicoceles with elevated fsh values, or low testosterone levels 4. varicoceles with scrotal pain 5. cosmetic indication 6. male infertility with pathological semen analysis and varicocele

Eligibility criteria:
inclusion criteria: * age more than 19 years old * primary varicocele exclusion criteria: * secondary varicocele recurrent varicocele age less than 19 years

Keywords: infertility pain pregnancy
treatment of congenital telangiectasia (coat's disease) with open-label anecortave acetate (15mg.)

Conditions: Coat's Disease

Summary: congenital telangiectasia or coat's disease is an uncommon disorder that involves the growth of blood vessels of the macula. these blood vessels msy extend beneth the retina to produce an area of sub-retinal neovascularization(growth of abnormal blood vessels under the retina which "leak" fluid, causing reduction in vision). limited forms of treatment are available in managing the neovascularization and its consequences. anecortave acetate injection will be considered as an attempt to control the growth of the abnormal blood vessels.

after evaluation, the patient will receive an injection of anecortave acetate (15mg) juxtascleral with a special cannula in the study eye. the patient will be contacted via phone on the day following the injection. if problem arises patient has to come back to see the study doctor. if patient is stable, a 3 month follow-up visit will be st-up.if the patient does not show improvement, the patient may be offered either thermal laser or pdt. if patient is stable, on the month 6 visit ,the patient will again receive another injection of anecortave acetate. the succeding follow-up schedule will be followed for a total of 24 months.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of congenital telangiectasia (coat's disease). 2. patients must be 18 years of age or older to receive treatment. 3. visual acuity of 20/30 to 20/320 study eye on the etdrs visual acuity chart. 4. visual acuity of 20/800 or better fellow eye on the etdrs visual acuity chart. exclusion criteria: 1. patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions. 2. patients who have undergone intraocular surgery within last 2 months. 3. patient participating in any other investigational drug study. 4. use of an investigational drug or treatment related or unrelated to their condition within 30 days prior to receipt of study medication. 5. inability to obtain photographs to document cnv (including difficulty with venous access). 6. patient with significant liver disease or uremia. 7. patient with known adverse reaction to fluorescein and indocyanine green or iodine. 8. patient has a history of any medical condition which would preclude scheduled visits or completion of study. 9. patient has had insertion of scleral buckle in the study eye 10. patient has received radiation treatment. 11. patient is on anticoagulant therapy with the exception of aspirin. 12. patient is pregnant or nursing.
fascia iliaca compartment block for proximal-end femur fractures

Conditions: Proximal Femur Fractures

Summary: fracture femur is a common injury which is associated with excruciating pain. positioning for neuraxial blocks is always challenging because even slight overriding of the fracture ends is intensely painful .it can causing major patient distress which accompanied by well-known physiological sequelae such as sympathetic activation causing tachycardia, hypotension, and increased cardiac work that may compromise high-risk cardiac patients. fascia iliaca compartment block is highly effective in blocking lateral cutaneous nerve of the thigh and femoral nerve. fascia iliaca compartment block is not only easy to perform but it is also associated with minimal risk as the local anesthetic is injected at a safe distance from the femoral artery and femoral nerve. it is always safe to perform the fascia iliaca compartment block prior to spinal anesthesia as the patient can respond during administration of the local anesthetic and can prevent intra-neuronal injections

on arrival to the pre-operative holding area half hour before the scheduled surgery. patient will be connected to basal monitoring devices; pulse oximetry and non- invasive blood pressure. fascia iliaca compartment block will be performed with the aid of ultrasound device in all cases.the injected local anesthetic solution will be prepared by a staff member who was not involved in the study) according to the randomization. after 20 minutes from the injection the investigators will assessed nerves that had been blocked. on arrival to the operative theater, under complete aseptic technique spinal anesthesia will be carried out in the sitting position (if there is severe pain at positioning we will use lateral position) at space between l3-4 or l4-5 using a 25-gauge spinal quincke needle. after feeling the desired space, the needle will be advanced (paramedian approach) till free flow of cerebrospinal fluid dropped from the needle then 15 mg hyperbaric bupivacaine+20mic fentanyl will be injected.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologist physical status i to iii * patients scheduled for fixation for proximal end femur fracture exclusion criteria: * patients refusal * morbid obese patients (bmi\>40) * bleeding diathesis * previous femoral bypass surgery * inguinal hernia * inflammation/infection over injection site * peripheral neuropathy * allergy to local anesthetics agents used. * severely altered consciousness level * psychiatric disorders * polytrauma
barley bread and metabolic disease

Conditions: Metabolic Syndrome

Summary: the aim of this study was to compare the metabolic effects of consuming whole barley bread and whole wheat bread, in healthy subjects. also, to investigate the effect of whole grain flour on mineral status.

generally, diet can be improved in order to lower diet-related diseases risk. however, the increasing prevalence rates of diet-related diseases indicate that, in practice, people's diet does not follow the recommendations. the intake of whole flour foods is consistently associated with reduced risk of type 2 diabetes and cardiovascular diseases in epidemiological studies, although the mechanisms of this association are unclear. here the aim is to compare the metabolic effects and mineral status of consumption of diet containing wholemeal barley bread versus whole meal wheat bread in healthy subjects. the intervention was designed as a randomized, cross over trial of 3-weeks duration. a total of 14 participants was included in the study. in one period subjects received wbb bread; in the second period, subjects received wwb bread. this bread is based on the recipe of egyptian baladi bread but formed in danish buns form. participants incorporated this bread into their normal habitual diet with regard to the study restrictions about other cereal food products. at the beginning and end of each intervention period blood was drawn and urine collected and stored for later analysis. the primary outcomes of this study are evaluation of ldl-c, insulin and glucose levels evaluated by analysis of fasting blood samples. furthermore, selected measures to evaluate scfa level in blood is to be evaluated. secondary outcomes include mineral status.

Eligibility criteria:
inclusion criteria: * like and tolerate wheat/ barley bread products. * age: 20 - 53 years * body mass index (bmi): 23 - 30 kg/m2 * weight stable (\<3 kg weight change during the last 6 months) * apparently healthy * informed consent signed * freezer capacity for 1 week bread provision * can attend all visits required for the study exclusion criteria: * wheat/gluten or barley intolerance * smoking on a daily basis * lactating (or lactating within 6 weeks prior to study start), pregnant (or pregnant within 3 months prior to study start) or wish to become pregnant during the study * diagnosed with any form of diabetes or cardiovascular disease * reported chronic gastrointestinal disorders * taking dietary supplements during or one month prior to the study * lack of cooperation and adherence to the protocol * use of prescription medication will be evaluated on an individual basis * blood donation within 3 months prior to study start or during the study * participation in other clinical trials
molecular endotypes of chronic idiopathic urticaria

Conditions: Chronic Urticaria, Idiopathic

Summary: this study plans to learn more about why some people with chronic idiopathic urticaria (ciu) respond to treatment with omalizumab (xolair). it will test people before they receive treatment with omalizumab as part of standard of care, to see if there are differences in their blood and skin that can predict who responds to treatment.


Eligibility criteria:
inclusion criteria: * ciu as defined as frequent urticarial lesions for ≥ 6 weeks * symptoms not controlled with standard dose antihistamines (loratadine 10mg daily, desloratadine 5mg daily, fexofenadine 180mg daily, cetirizine 10mg daily, or levocetirizine 5mg daily) * planned initiation of treatment with omalizumab (xolair) as part of standard of care for antihistamine-refractory urticaria exclusion criteria: * use of immunomodulatory drugs in the past 1 month prior to beginning the study * use of systemic steroids in the past 1 month prior to beginning the study * use of omalizumab in the past 3 months prior to beginning the study * use of any investigational agent in the past 30 days * untreated intercurrent illness * severe asthma * primary diagnosis of flushing